Impact of Late Treatment-Related Toxicity on Quality of Life Among Patients With Head and Neck Cancer Treated With Radiotherapy

2008 ◽  
Vol 26 (22) ◽  
pp. 3770-3776 ◽  
Author(s):  
Johannes A. Langendijk ◽  
Patricia Doornaert ◽  
Irma M. Verdonck-de Leeuw ◽  
Charles R. Leemans ◽  
Neil K. Aaronson ◽  
...  

Purpose To investigate the impact of treatment-related toxicity on health-related quality of life (HRQoL) among patients with head and neck squamous cell carcinoma treated with radiotherapy either alone or in combination with chemotherapy or surgery. Patients and Methods The study sample was composed of 425 disease-free patients. Toxicity was scored according to the European Organisation for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) late radiation-induced morbidity scoring system. HRQoL was assessed using the EORTC Quality of Life Questionnaire C30. These assessments took place at 6, 12, 18, and 24 months after completion of radiotherapy. The analysis was performed using a multivariate analysis of variance. Results Of the six RTOG scales investigated, two significantly affected self-reported HRQoL, salivary gland (RTOGxerostomia) and esophagus/pharynx (RTOGswallowing). Although RTOGxerostomia was reported most frequently, HRQoL was most affected by RTOGswallowing, particularly in the first 18 months after completion of radiotherapy. Conclusion Late radiation-induced toxicity, particularly RTOGswallowing and RTOGxerostomia, has a significant impact on the more general dimensions of HRQoL. These findings suggest that the development of new radiation-induced delivery techniques should not only focus on reduction of the dose to the salivary glands, but also on anatomic structures that are involved in swallowing.

Oral Oncology ◽  
2011 ◽  
Vol 47 (8) ◽  
pp. 768-774 ◽  
Author(s):  
Bram L.T. Ramaekers ◽  
Manuela A. Joore ◽  
Janneke P.C. Grutters ◽  
Piet van den Ende ◽  
Jos de Jong ◽  
...  

2020 ◽  
pp. 014556132096172
Author(s):  
Charlotte Montalvo ◽  
Caterina Finizia ◽  
Nina Pauli ◽  
Bodil Fagerberg-Mohlin ◽  
Paulin Andréll

Trismus is a common symptom in patients with head and neck cancer that affects many aspects of daily life negatively. The aim of this study was to investigate the impact of structured exercise with the jaw-mobilizing device TheraBite on trismus, trismus-related symptomatology, and health-related quality of life (HRQL) in patients with head and neck cancer. Fifteen patients with trismus (maximum interincisal opening [MIO] ≤35 mm) after oncologic treatment for head and neck cancer, underwent a 10-week exercise program with the TheraBite device and were followed regularly. Time between oncologic treatment and start of TheraBite exercise ranged from 0.7 to 14.8 years (average 6.2 years). MIO, trismus-related symptoms, and HRQL was assessed before and after exercise and after 6 months. A significant improvement in MIO was observed post-exercise (3.5 mm, 15.3%, p = 0.0002) and after 6-month of follow-up (4.7 mm, 22.1%, p = 0.0029). A statistically significant correlation was found between increased MIO and fewer trismus-related symptoms. In conclusion, exercise with TheraBite improved MIO and trismus-related symptoms in patients with trismus secondary to head and neck cancer. Structured exercise with the jaw-mobilizing device seems to be beneficial for patients with trismus independent of time since oncologic treatment.


Cephalalgia ◽  
1997 ◽  
Vol 17 (8) ◽  
pp. 867-872 ◽  
Author(s):  
NC Santanello ◽  
AB Polis ◽  
SL Hartmaier ◽  
MS Kramer ◽  
GA Block ◽  
...  

A validated migraine-specific questionnaire (24-h Migraine Quality of Life Questionnaire1: 24-h MQoLQ) was used to assess the impact of migraine and migraine therapy on health related quality of life during an acute migraine attack. Male and female migraineurs aged 18-55 years were randomized to placebo ( n = 41), rizatriptan 2.5 mg ( n = 47), 5 mg ( n = 74), or 10 mg ( n = 85) in a triple-blind, placebo-controlled clinical trial. Rizatriptan 5 mg and 10 mg were significantly more efficacious than placebo on pain relief and functional disability. After accounting, for multiple comparisons to placebo, rizatriptan 10 mg showed significantly better responses compared to placebo on three of five domains of 24-h MQoLQ (social functioning, migraine symptoms, and feelings/concerns). The O'Brien's Rank Sum Test statistic showed a statistically significant overall difference on the 24-h MQoLQ between the 10 mg rizatriptan and placebo groups ( p = 0.005) and for the overall close trend ( p 0.001).


Author(s):  
Allisson Filipe Lopes Martins ◽  
Marília Oliveira Morais ◽  
Sebastião Silvério de Sousa-Neto ◽  
Ana Paula Gonçalves de Jesus ◽  
Tulio Eduardo Nogueira ◽  
...  

2012 ◽  
Vol 103 ◽  
pp. S263-S264
Author(s):  
W. Schaake ◽  
E.M. Wiegman ◽  
M. de Groot ◽  
H.P. van der Laan ◽  
J.A. Langendijk ◽  
...  

2010 ◽  
Vol 12 (2) ◽  
pp. 83-91 ◽  
Author(s):  
Vivek S. Pawar ◽  
Gauri Pawar ◽  
Lesley-Ann Miller ◽  
Iftekhar Kalsekar ◽  
Jan Kavookjian ◽  
...  

The aim of this study was to evaluate the impact of visual impairment on health-related quality of life (HRQOL) in patients with multiple sclerosis (MS). Patients at an outpatient MS clinic were asked to complete a battery of patient-reported outcome questionnaires. Health-related quality of life was measured using the Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HAQUAMS), while visual impairment was measured using the Visual Function Questionnaire (VFQ). Hierarchical regression was used to determine the relative contribution of visual impairment to HRQOL. Usable responses were obtained for 116 MS patients. Those with higher levels of visual impairment (lower scores on the VFQ) reported significantly lower HRQOL (β = –0.01, P = .0007). Visual impairment also explained an additional 4% variance in the HRQOL scores, independent of disability and depression (ΔR2 = 0.04, F7,108 = 36.58). Overall, disability was the strongest predictor of HRQOL, explaining over 60% of the variation in HRQOL scores. The model explained 70% of the total variance in HRQOL. Given the prevalence of visual impairment and its influence on overall HRQOL, MS patients should be routinely screened using standard ophthalmic examination procedures or self-administered questionnaires such as the VFQ.


RSBO ◽  
2017 ◽  
Vol 1 (1) ◽  
pp. 24
Author(s):  
Marcelo Carlos Bortoluzzi ◽  
Cintia Cella ◽  
Suelen Franke Haus

Introduction: Dentofacial deformity (DFD) may be defined as facial and dental disproportions great enough to affect significantly the individual’s quality of life (QoL). Objective: This study aimed to verify and compare the impacts of and differences in QoL in individuals with and without DFD. Material and methods: The impact of DFD on QoL was evaluated through the following questionnaires:Short Form Health Survey (SF36), a generic Oral Health Related Quality of Life (OHRQoL) questionnaire (Oral Health Impact Profile Questionnaire – OHIP-49), a condition-specific questionnaire for DFD (Orthognathic Quality of Life Questionnaire – OQLQ) and a single question answered by Visual Analogue Scale (VAS). Results: Greater and negative impacts on QoL were observed in patientswith DFD in all domains of OQLQ and OHIP; and in two domains of SF36: emotional well-being and social functioning. Conclusion: DFD greatly and negatively impacted on QoL of individuals with DFD greater mainly evidenced through general and specific OHRQoL questionnaires.


2015 ◽  
Vol 97 (5) ◽  
pp. 359-363 ◽  
Author(s):  
SN Rogers ◽  
ES Hogg ◽  
WKA Cheung ◽  
LKL Lai ◽  
P Jassal ◽  
...  

Introduction Health related quality of life information gives patients and carers an indication of how they will be affected following treatment. Such knowledge can promote realistic expectations and help patients come to terms with their outcome. The aim of this paper is to describe the background development of patient information sheets produced at our unit. Methods The data were compiled using a common head and neck cancer specific quality of life questionnaire (University of Washington Quality of Life [UW-QOL]). There are 12 domains comprising activity, appearance, anxiety, chewing, mood, pain, recreation, saliva, shoulder, speech, swallowing and taste. The data were collected over 19 years at our unit and focus on follow-up records at around 2 years as this gives a good indication of health related quality of life in survivorship. UW-QOL questionnaires were available from 1,511 patients treated following primary diagnosis of head and neck cancer, and there were 24 subgroups based on cancer site, stage and treatment. There were 2 other subgroups: 132 having transoral laser resection and 176 having laryngectomy. Results The patient and carer research forum helped to design the information sheets, which display overall quality of life, percentages with ‘good’ outcome and ‘significant problem’ by domain, and the most important domains. Three examples are included in this paper: early stage oral cancer treated by surgery alone, early laryngeal cancer treated by surgery alone, and late stage oropharyngeal cancer treated by surgery and postoperative radiotherapy. All 26 subgroup information sheets are available in booklet form and on the internet. Conclusions How the surgical community best utilises this type of resource needs further research.


Sign in / Sign up

Export Citation Format

Share Document